CPRX Company Profile and Key Details

Q: Who are the executives of CPRX?

Mr. Brian Elsbernd J.D.Chief Compliance Officer & Chief Legal OfficerDr. Gary Ingenito M.D., Ph.D.Chief Medical & Regulatory OfficerMr. Patrick J. McEnanyCo-Founder, Chairman, Pres & Chief Executive OfficerMr. Philip B. SchwartzCorporation Sec.Dr. Steven R. Miller Ph.D.Chief Operating Officer & Chief Scientific OfficerDr. Preethi Sundaram Ph.D.Chief Strategy OfficerMr. Jeffrey Del CarmenChief Commercial OfficerMs. Alicia Grande C.M.A., CPA, CMA, CPAChief Accounting Officer, Vice President, Treasurer & Chief Financial OfficerMr. Pete Curry Sr.Vice President of SalesDr. Stanley Iyadurai M.D., Ph.D.Senior Vice President of Medical Affairs & Drug DiscoveryMs. Mary ColemanVice President of Investment Relations

NASDAQ : CPRX

Catalyst Pharmaceuticals

$29.27

1.9+6.94%

At Close 4:00 PM

72.2

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Catalyst Pharmaceuticals, Inc. (CPRX) stock surged +6.94%, trading at $29.27 on NASDAQ, up from the previous close of $27.37. The stock opened at $27.56, fluctuating between $27.30 and $32.56 in the recent session.

Stock Snapshot

27.37

Prev. Close

3.57B

Market Cap

27.3

Day Low

17.42

P/E Ratio

1.68

EPS (TTM)

0.26

Cash Flow per Share

27.56

Open

122.12M

Number of Shares

32.56

Day High

93.78%

Free Float in %

3.63

Book Value

9.23M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 27, 2026	27.56	32.56	27.30	29.27	9.32M
Apr 23, 2026	25.99	27.71	25.89	27.68	2.91M
Apr 22, 2026	25.82	25.96	25.55	25.94	702.61K
Apr 21, 2026	25.91	26.03	25.60	25.64	835.29K
Apr 20, 2026	26.20	26.42	25.89	26.07	1.55M
Apr 17, 2026	26.20	26.36	25.85	26.26	3.28M
Apr 16, 2026	25.74	26.04	25.58	25.89	912.69K
Apr 14, 2026	25.65	26.45	25.51	26.19	2.11M
Apr 13, 2026	24.80	25.41	24.69	25.34	1.11M
Apr 10, 2026	25.54	25.57	24.83	24.94	1.28M
Apr 09, 2026	24.98	25.82	24.92	25.60	1.53M
Apr 08, 2026	25.50	25.80	25.23	25.31	1.35M
Apr 07, 2026	24.98	25.16	24.82	24.99	1.19M
Apr 06, 2026	24.69	25.00	24.54	24.98	820.03K
Apr 02, 2026	24.54	24.79	24.38	24.69	616.05K
Apr 01, 2026	25.00	25.14	24.64	24.82	1.45M
Mar 31, 2026	24.01	24.83	24.01	24.76	995.61K
Mar 30, 2026	23.40	23.88	23.05	23.78	801.18K
Mar 27, 2026	24.15	24.29	23.39	23.40	754.79K
Mar 25, 2026	23.41	23.81	23.21	23.80	1.01M

Contact Details

Coral Gables, FL 33134

United States

https://www.catalystpharma.com 305 420 3200

About Company

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Stock Peers

ARGX

3.49+0.45%

argenx SE$783.74 REGN

-7.13-0.95%

Regeneron Pharmaceuticals, Inc.$744.44 UTHR

-0.17-0.03%

United Therapeutics Corporation$566.99 MDGL

7.7+1.50%

Madrigal Pharmaceuticals, Inc.$520.09 VRTX

-4.285-1.00%

Vertex Pharmaceuticals Incorporated$426.01 PRAX

-13.83-4.01%

Praxis Precision Medicines, Inc.$330.99 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

2.97+0.97%

Alnylam Pharmaceuticals, Inc.$308.51 KRYS

0.23+0.08%

Krystal Biotech, Inc.$272.75 LGND

10.52+4.55%

Ligand Pharmaceuticals Incorporated$241.79

Company Overview

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) closed at $29.27 USD, gaining $1.90 (6.94%) from the previous close of $27.37. The stock is currently mid-range between its 52-week high and low $19.05 and $32.56. With a market capitalization of about $3.57 billion, Catalyst Pharmaceuticals, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.66). Key stats such as the average daily volume over the past year has been around 1.42 million shares, trading with heavier-than-usual volume. Headquartered in Coral Gables, FL, Catalyst Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Richard John Daly, the company employs approximately 181 people and listed since November 08, 2006. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 1.8%, SMA50 4.07%, SMA200 11.46%). The stock’s 14-day RSI is 57.96 (neutral), while the ATR of 0.85 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.4% below its high and over 30.6% above its low. Average 10-day trading volume of 3.06 million shares is significantly above the 3-month average of 1.41 million, indicating heightened recent market interest.

Valuation Metrics

Catalyst Pharmaceuticals, Inc. trades at a P/E ratio of 16.78, slightly below the S&P 500 average, with a price-to-sales ratio of 6.1 and a price-to-book ratio of 3.77 trading at moderately above to book value. The P/FCF stands at 17.22, also above market averages.

Dividend & Fair Value

Catalyst Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.12. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Catalyst Pharmaceuticals, Inc. generated EPS of $1.71 over the past year. Five-year average earnings growth is 34.27%. Wall Street analysts project EPS growth of 5.45% annually over the next five years. The latest quarter delivered EPS of $0.42. The next quarter is forecast at $0.42. Next year's EPS is expected at $115.88. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $35.00 to $33.00. The high target offers 19.58% upside. The low target suggests 12.74% downside. The mean target is $34.00. This offers 16.16% upside. Catalyst Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -18.57%. The prior quarter beat by 17.24%. Over the last six quarters, Apple has recorded several small beats. These include -54.76% in August 07, 2024.

Shareholding & Insider Activity

Catalyst Pharmaceuticals, Inc. has 122.39 million shares outstanding. The public float is 114.77 million shares, elevated short interest at 8.28% of float. This equals 7.93 million shares. The short ratio is 5.56 days. Institutional investors hold 91.27% of the float. Insiders own 6.33%. MCENANY PATRICK J holds 4.28 million shares, Miller Steve has 949.66 thousand shares and O'Keeffe Charles B has 565.06 thousand shares. Over the past six months, insider transactions show net selling. They sold 57.73 thousand shares across 3 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Catalyst Pharmaceuticals generated $398.20M in revenue, or $3.50 per share. Gross margin was 78.77%, operating margin 21.80%, and net profit margin 17.93%. Returns are healthy, with ROA at 15.13% and ROE at 18.41%.
On valuation metrics, Catalyst Pharmaceuticals trades at a P/E of 16.78, P/S of 6.10 and P/B of 3.77. The current ratio is 6.08 and quick ratio is 5.82. Operationally, the company’s inventory turnover is 2.35 and cash conversion cycle is 188.10 days. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of 74.87.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Catalyst Pharmaceuticals posted revenue of $398.20M, down slightly from $214.20M in the prior quarter. Gross profit was $313.67M (margin 78.77%). Operating income was $86.81M (margin 21.8%). Net income was$71.41M (EPS $0.67).
The company ended the quarter with $137.64M in cash and short-term investments, a total debt of $3.56M, and net debt of - $134.08M. Total assets were $471.91M, with equity of $387.88M. Financials further reflected stability, with operating cash flow of $143.60M, free cash flow of - $54.92M, and capital expenditures of - $198.52M.

Price Forecast & Outlook

Our AI price prediction model suggests that Catalyst Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.78%, with price expected at $30.67 by May 11, 2026, within a range of $30.03 to $31.32 3-Month Outlook: Projected rise of 41.78%, reaching $41.50 by July 24, 2026, with a range of $40.46 to $42.54. 1-Year Outlook: Projected gain of 15.58%, with price at $33.83 by April 27, 2027, within a range of $33.11 to $34.62.

Key Takeaways

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) shares are flat 0.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Catalyst Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of 16.78. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $20.33, suggesting -30.54% downside. Our AI forecast model points to short-term strength (4.78% over two weeks), a medium-term rise (41.78% over three months), and a longer-term gain (15.58% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Catalyst Pharmaceuticals, Inc. (CPRX) stock price?

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) stock price is $29.27 in the last trading session. During the trading session, CPRX stock reached the peak price of $32.56 while $27.30 was the lowest point it dropped to. The percentage change in CPRX stock occurred in the recent session was 6.94% while the dollar amount for the price change in CPRX stock was $1.90.

CPRX's industry and sector of operation?

The NASDAQ listed CPRX is part of Biotechnology industry that operates in the broader Healthcare sector. Catalyst Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CPRX?

Mr. Brian Elsbernd J.D.
Chief Compliance Officer & Chief Legal Officer
Dr. Gary Ingenito M.D., Ph.D.
Chief Medical & Regulatory Officer
Mr. Patrick J. McEnany
Co-Founder, Chairman, Pres & Chief Executive Officer
Mr. Philip B. Schwartz
Corporation Sec.
Dr. Steven R. Miller Ph.D.
Chief Operating Officer & Chief Scientific Officer
Dr. Preethi Sundaram Ph.D.
Chief Strategy Officer
Mr. Jeffrey Del Carmen
Chief Commercial Officer
Ms. Alicia Grande C.M.A., CPA, CMA, CPA
Chief Accounting Officer, Vice President, Treasurer & Chief Financial Officer
Mr. Pete Curry Sr.
Vice President of Sales
Dr. Stanley Iyadurai M.D., Ph.D.
Senior Vice President of Medical Affairs & Drug Discovery
Ms. Mary Coleman
Vice President of Investment Relations

How CPRX did perform over past 52-week?

CPRX's closing price is 53.65% higher than its 52-week low of $19.05 where as its distance from 52-week high of $32.56 is -10.1%.

How many employees does CPRX have?

Number of CPRX employees currently stands at 181.

Link for CPRX official website?

Official Website of CPRX is: https://www.catalystpharma.com

How do I contact CPRX?

CPRX could be contacted at phone 305 420 3200 and can also be accessed through its website. CPRX operates from 355 Alhambra Circle, Coral Gables, FL 33134, United States.

How many shares of CPRX are traded daily?

CPRX stock volume for the day was 9.23M shares. The average number of CPRX shares traded daily for last 3 months was 1.42M.

What is the market cap of CPRX currently?

The market value of CPRX currently stands at $3.57B with its latest stock price at $29.27 and 122.12M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	181
Beta	0.66
Sales or Revenue	$398.20M
5Y Sales Change%	768.088%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CPRX Company Profile and Key Details

Catalyst Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Valuation Metrics

Earnings & Analyst Outlook

Shareholding & Insider Activity

Dividend & Fair Value

Price Forecast & Outlook

Key Takeaways

Financial & Profitability Overview

Quarterly Financial Highlights